Mark P Lythgoe (M P Lythgoe)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 20

Top Venues

JCO oncology practice

Prostate cancer and prostatic diseases

Nature reviews. Clinical oncology

Cancers

Imperial College London

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Imperial College London Sep 01 2019

United Kingdom

Clinical Research Fellow :: Surgery & Cancer

Publications

David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020. JCO oncology practice (2024)
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020. JCO oncology practice 20 (4) (2024)
David J Benjamin, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020. JCO oncology practice 20 (4) (2024)
David J Benjamin, Anshu Shrestha, Dimitra Fellman, Rosemary D Cress, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate cancer and prostatic diseases (2023)
Viktoria Gloy, Andreas Michael Schmitt, Pascal Düblin, Julian Hirt, Cathrin Axfors, Hanna Kuk, Tiago V Pereira, Clara Locher, Laura Caquelin, Martin Walter-Claudi, Mark P Lythgoe, Amanda Herbrand, Benjamin Kasenda, Lars G Hemkens
The Evidence Base of US Food and Drug Administration Approvals of Novel Cancer Therapies from 2000 to 2020. International journal of cancer (2023)
Max Julve, Oliver Kennedy, Adam Enver Frampton, Izhar Bagwan, Mark P Lythgoe
Gene of the month: cancer testis antigen gene 1b (NY-ESO-1). Journal of clinical pathology (2023)
David J Benjamin, Anshu Shrestha, Dimitra Fellman, Rosemary D Cress, Mark P Lythgoe, Arash Rezazadeh Kalebasty
Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate cancer and prostatic diseases (2023)
Viktoria Gloy, Andreas Michael Schmitt, Pascal Düblin, Julian Hirt, Cathrin Axfors, Hanna Kuk, Tiago V Pereira, Clara Locher, Laura Caquelin, Martin Walter-Claudi, Mark P Lythgoe, Amanda Herbrand, Benjamin Kasenda, Lars G Hemkens
The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. International journal of cancer (2023)
David J Benjamin, Mark P Lythgoe
The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back? Nature reviews. Clinical oncology (2023)
Mark P Lythgoe
No new 'mabs' in medicine-New nomenclature for monoclonal antibodies. British journal of pharmacology 179 (24) (2022)
Mark P Lythgoe, Vinay Prasad
Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology. British journal of cancer 127 (5) (2022)
Sofía Mirón-Barroso, Joana S Correia, Adam Enver Frampton, Mark P Lythgoe, James Clark, Laura Tookman, Silvia Ottaviani, Castellano L, Alexandra E Porter, Theoni K Georgiou, Jonathan Krell
Polymeric Carriers for Delivery of RNA Cancer Therapeutics. Non-coding RNA 8 (4) (2022)
Sarah P Blagden, Ly-Mee Yu, Stephanie Ellis, Helen Hughes, Abeer M Shaaban, Jonathan Fennelly-Barnwell, Mark P Lythgoe, Alison M Cooper, Francois M Maignen, Sean W Buckland, Pamela R Kearns, Louise C Brown, null null
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective. British journal of cancer (2022)
Mark P Lythgoe, J Krell, P Savage, V Prasad
Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020. Prostate cancer and prostatic diseases 24 (4) (2021)
Rohini Sharma, Mark P Lythgoe, Bhavandeep Slaich, Nishil Patel
Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. Cancers 13 (16) (2021)
Rebecca Abdelmalak, Mark P Lythgoe, Joanne Evans, Michael Flynn, Justin Waters, Andy Webb, David James Pinato, Rohini Sharma
Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. Cancers 13 (16) (2021)
Mark P Lythgoe, Vinay Prasad
The FDA's latest move to expand eligibility for oncology trials - a double-edged sword? Nature reviews. Clinical oncology 18 (12) (2021)
Mark P Lythgoe, J Krell, I A McNeish, L Tookman
Safe administration of chemotherapy in mast cell activation syndrome. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 27 (4) (2020)
Perrine Janiaud, Cathrine Axfors, Janneke Van't Hooft, Ramon Saccilotto, Arnav Agarwal, Christian Appenzeller-Herzog, Despina G Contopoulos-Ioannidis, Valentin Danchev, Ulrich Dirnagl, Hannah Ewald, Gerald Gartlehner, Steven N Goodman, Noah A Haber, Angeliki Diotima Ioannidis, John P A Ioannidis, Mark P Lythgoe, Wenyan Ma, Malcolm Macleod, Mario Malički, Joerg J Meerpohl, Yan Min, David Moher, Blin Nagavci, Florian Naudet, Christiane Pauli-Magnus, Jack W O'Sullivan, Nico Riedel, Jan A Roth, Mandy Sauermann, Stefan Schandelmaier, Andreas M Schmitt, Benjamin Speich, Paula R Williamson, Lars G Hemkens
The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research 9 (2020)
Perrine Janiaud, Cathrine Axfors, Janneke Van't Hooft, Ramon Saccilotto, Arnav Agarwal, Christian Appenzeller-Herzog, Despina G Contopoulos-Ioannidis, Valentin Danchev, Ulrich Dirnagl, Hannah Ewald, Gerald Gartlehner, Steven N Goodman, Noah A Haber, Angeliki Diotima Ioannidis, John P A Ioannidis, Mark P Lythgoe, Wenyan Ma, Malcolm Macleod, Mario Malički, Joerg J Meerpohl, Yan Min, David Moher, Blin Nagavci, Florian Naudet, Christiane Pauli-Magnus, Jack W O'Sullivan, Nico Riedel, Jan A Roth, Mandy Sauermann, Stefan Schandelmaier, Andreas M Schmitt, Benjamin Speich, Paula R Williamson, Lars G Hemkens
The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research (2020)

Mark P Lythgoe.css-eqlu8i{font-size:small;padding-left:4px;} (M P Lythgoe)

Publication Activity (10 Years)

Top Topics

Top Venues

Mark P Lythgoe (M P Lythgoe)